Skip to main content
FDA grants priority review for AstraZeneca candidate for breast cancer
10/17/2019

AstraZeneca announced that its investigational breast cancer treatment, trastuzumab deruxtecan, will undergo priority review by the FDA. The treatment was developed to treat HER2-positive metastatic breast cancer.

Full Story: